PMID- 35320883
OWN - NLM
STAT- MEDLINE
DCOM- 20220422
LR  - 20220712
IS  - 2005-0399 (Electronic)
IS  - 2005-0380 (Print)
IS  - 2005-0380 (Linking)
VI  - 33
IP  - 3
DP  - 2022 May
TI  - Posterior pelvic exenteration for ovarian cancer: surgical and oncological 
      outcomes.
PG  - e31
LID - 10.3802/jgo.2022.33.e31 [doi]
LID - e31
AB  - OBJECTIVE: Posterior pelvic exenteration (PPE) can be required to achieve 
      complete resection in ovarian cancer (OC) patients with large pelvic disease. 
      This study aimed to analyze morbidity, complete resection rate, and survival of 
      PPE. METHODS: Ninety patients who underwent PPE in our Comprehensive Cancer 
      Center between January 2010 and February 2021 were retrospectively identified. To 
      analyze practice evolution, 2 periods were determined: P1 from 2010 to 2017 and 
      P2 from 2018 to 2021. RESULTS: A 82.2% complete resection rate after PPE was 
      obtained, with rectal anastomosis in 96.7% of patients. Complication rate was at 
      30% (grade 3 in 9 patients), without significant difference according to periods 
      or quality of resection. In a binary logistic regression adjusted on age and 
      stoma, only age of 51-74 years old was associated with a lower rate of 
      complication (odds ratio=0.223; p=0.026). Median overall and disease-free 
      survivals (OS and DFS) from initial diagnosis were 75.21 and 29.84 months, 
      respectively. A negative impact on OS and DFS was observed in case of incomplete 
      resection, and on DFS in case of final cytoreductive surgery (FCS: after >/=6 
      chemotherapy cycles). Age >/=75-years had a negative impact on DFS for new OC 
      surgery. For patients with complete resection, OS and DFS were decreased in case 
      of interval cytoreductive surgery and FCS in comparison with primary 
      cytoreductive surgery. CONCLUSION: PPE is an effective surgical measure to 
      achieve complete resection for a majority of patients. High rate of colorectal 
      anastomosis was achieved without any mortality, with acceptable morbidity and 
      high protective stoma rate.
CI  - Copyright (c) 2022. Asian Society of Gynecologic Oncology, Korean Society of 
      Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
FAU - Houvenaeghel, Gilles
AU  - Houvenaeghel G
AUID- ORCID: 0000-0002-4384-6255
AD  - Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.
AD  - Faculty of Medical Sciences, Aix-Marseille University, CNRS, Inserm, CRCM, 
      Marseille, France. houvenaeghelg@ipc.unicancer.fr.
FAU - de Nonneville, Alexandre
AU  - de Nonneville A
AUID- ORCID: 0000-0001-6710-8284
AD  - Institut Paoli Calmettes, Department of Medical Oncology, Marseille, France.
FAU - Blache, Guillaume
AU  - Blache G
AUID- ORCID: 0000-0003-0140-1431
AD  - Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.
FAU - Buttarelli, Max
AU  - Buttarelli M
AUID- ORCID: 0000-0002-6036-8769
AD  - Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.
FAU - Jauffret, Camille
AU  - Jauffret C
AUID- ORCID: 0000-0002-8011-2429
AD  - Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.
FAU - Mokart, Djamel
AU  - Mokart D
AUID- ORCID: 0000-0003-1711-463X
AD  - Institut Paoli Calmettes, Department of Anesthesiology and Critical Care, 
      Marseille, France.
FAU - Sabiani, Laura
AU  - Sabiani L
AUID- ORCID: 0000-0001-7903-7380
AD  - Institut Paoli Calmettes, Department of Surgical Oncology, Marseille, France.
LA  - eng
PT  - Journal Article
DEP - 20220204
PL  - Korea (South)
TA  - J Gynecol Oncol
JT  - Journal of gynecologic oncology
JID - 101483150
SB  - IM
CIN - J Gynecol Oncol. 2022 May;33(3):e41. PMID: 35320890
MH  - Aged
MH  - Carcinoma, Ovarian Epithelial/surgery
MH  - Cytoreduction Surgical Procedures/adverse effects
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - *Ovarian Neoplasms/etiology/surgery
MH  - *Pelvic Exenteration/adverse effects
MH  - Retrospective Studies
PMC - PMC9024184
OTO - NOTNLM
OT  - Ovarian Cancer
OT  - Pelvic Exenteration
OT  - Prognosis
OT  - Surgery
OT  - Survival
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2022/03/24 06:00
MHDA- 2022/04/23 06:00
PMCR- 2022/05/01
CRDT- 2022/03/23 20:07
PHST- 2021/08/13 00:00 [received]
PHST- 2021/10/08 00:00 [revised]
PHST- 2022/01/02 00:00 [accepted]
PHST- 2022/03/24 06:00 [pubmed]
PHST- 2022/04/23 06:00 [medline]
PHST- 2022/03/23 20:07 [entrez]
PHST- 2022/05/01 00:00 [pmc-release]
AID - 33.e31 [pii]
AID - 10.3802/jgo.2022.33.e31 [doi]
PST - ppublish
SO  - J Gynecol Oncol. 2022 May;33(3):e31. doi: 10.3802/jgo.2022.33.e31. Epub 2022 Feb 
      4.